E-viri
PDF
Recenzirano
Odprti dostop
-
Qin, Haixia; Patel, Manish R
International journal of molecular sciences, 03/2022, Letnik: 23, Številka: 6Journal Article
With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhibitors, larotrectinib and entrectinib. Both medications have excellent CNS penetration. This manuscript will review available data on targeting NTRK fusions in NSCLC and mechanisms of drug resistance.
